Align Technology, Inc. (NASDAQ:ALGN) Shares Bought by Dohj LLC

Dohj LLC increased its stake in Align Technology, Inc. (NASDAQ:ALGN) by 84.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,611 shares of the medical equipment provider’s stock after purchasing an additional 739 shares during the quarter. Dohj LLC’s holdings in Align Technology were worth $441,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. EFG Asset Management Americas Corp. raised its position in Align Technology by 3.6% in the fourth quarter. EFG Asset Management Americas Corp. now owns 1,167 shares of the medical equipment provider’s stock worth $320,000 after acquiring an additional 41 shares in the last quarter. Dfpg Investments LLC raised its position in Align Technology by 3.3% in the fourth quarter. Dfpg Investments LLC now owns 1,327 shares of the medical equipment provider’s stock worth $340,000 after acquiring an additional 42 shares in the last quarter. Richard W. Paul & Associates LLC raised its holdings in Align Technology by 2.8% during the 4th quarter. Richard W. Paul & Associates LLC now owns 1,669 shares of the medical equipment provider’s stock worth $457,000 after buying an additional 45 shares during the period. Valley National Advisers Inc. raised its holdings in Align Technology by 29.7% during the 3rd quarter. Valley National Advisers Inc. now owns 214 shares of the medical equipment provider’s stock worth $65,000 after buying an additional 49 shares during the period. Finally, Jag Capital Management LLC raised its holdings in Align Technology by 4.1% during the 3rd quarter. Jag Capital Management LLC now owns 1,258 shares of the medical equipment provider’s stock worth $384,000 after buying an additional 50 shares during the period. Institutional investors and hedge funds own 88.43% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on ALGN shares. Piper Sandler restated an “overweight” rating and set a $375.00 price objective (up previously from $355.00) on shares of Align Technology in a report on Thursday. Leerink Partnrs restated a “market perform” rating on shares of Align Technology in a report on Monday, February 26th. Morgan Stanley boosted their price objective on Align Technology from $344.00 to $360.00 and gave the stock an “overweight” rating in a report on Thursday. The Goldman Sachs Group upped their target price on Align Technology from $197.00 to $225.00 and gave the company a “sell” rating in a report on Friday, February 2nd. Finally, Stifel Nicolaus upped their target price on Align Technology from $350.00 to $400.00 and gave the company a “buy” rating in a report on Thursday, April 18th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $341.36.

Insider Buying and Selling at Align Technology

In other Align Technology news, EVP Emory Wright sold 2,524 shares of the stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $287.45, for a total transaction of $725,523.80. Following the transaction, the executive vice president now owns 709 shares in the company, valued at $203,802.05. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, Director Joseph Lacob sold 15,000 shares of the firm’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $303.22, for a total value of $4,548,300.00. Following the sale, the director now owns 131,994 shares in the company, valued at $40,023,220.68. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Emory Wright sold 2,524 shares of the firm’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $287.45, for a total value of $725,523.80. Following the completion of the transaction, the executive vice president now directly owns 709 shares of the company’s stock, valued at $203,802.05. The disclosure for this sale can be found here. Insiders have sold a total of 27,524 shares of company stock worth $8,403,924 over the last 90 days. Insiders own 0.64% of the company’s stock.

Align Technology Price Performance

NASDAQ:ALGN traded down $1.48 during mid-day trading on Friday, reaching $309.02. The stock had a trading volume of 737,294 shares, compared to its average volume of 636,306. The business’s 50 day moving average is $313.38 and its 200 day moving average is $270.98. Align Technology, Inc. has a fifty-two week low of $176.34 and a fifty-two week high of $413.20. The stock has a market cap of $23.25 billion, a P/E ratio of 50.91, a PEG ratio of 5.56 and a beta of 1.65.

Align Technology (NASDAQ:ALGN) last announced its quarterly earnings results on Wednesday, January 31st. The medical equipment provider reported $1.91 EPS for the quarter, beating the consensus estimate of $1.78 by $0.13. Align Technology had a return on equity of 14.15% and a net margin of 11.80%. The company had revenue of $956.73 million for the quarter, compared to the consensus estimate of $928.57 million. Equities analysts expect that Align Technology, Inc. will post 7.69 EPS for the current year.

Align Technology Company Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.